Industry in brief | Galenica, Adamed, Sanofi

Industry in brief | Galenica, Adamed, Sanofi

9 April 2020 - Deborah Wilkes

Galenica has issued financial guidance in light of the COVID-19 pandemic, Adamed has launched Maxon Forte (sildenafil) in Poland, and Sanofi Consumer Healthcare is partnering with Plug and Play Japan.

Galenica provides COVID-19 update

Switzerland’s Galenica said pharmacies and other companies within the group had recorded “extraordinarily high sales” in March 2020 due to the COVID-19 pandemic.

Volumes at Galenica’s logistics companies, which supply the entire healthcare market in Switzerland, had “increased massively”, added the company, pointing out that capacity limits in distribution centres had been “substantially exceeded on certain days”.

Since the beginning of April, however, there had been a “sharp decline” in frequency and sales in pharmacies, said Galenica, as well as a corresponding decline for the logistics companies.

“Depending on its impact and duration,” commented Galenica, “this extraordinary situation could have a negative impact on the 2020 result.”

Adamed launches Maxon Forte

Poland’s Adamed has switched a 50mg sildenafil medicine from prescription-to-OTC status in its home market. The product for erectile dysfunction is called Maxon Forte.

The move comes four years after Adamed launched 25mg sildenafil tablets under the Maxon Active brand in Poland.

At the time, Poland was only the second country to allow sildenafil – the active ingredient of Pfizer's Viagra – to be sold without a prescription (click here to read the News story).

The Polish pharmaceutical company said it had carried out a multi-centre, intervention clinical trial for 50mg sildenafil involving 403 participants. The aim of the trial was to show that patients could safely use sildenafil at a dose of 50mg on their own.

Maxon Forte is supplied in a pack of two, 50mg sildenafil tablets.

Sanofi partners with Plug and Play Japan

Sanofi Consumer Healthcare has become an “anchor partner” of Plug and Play Japan’s Hardtech & Health programme in Kyoto.

Based in the US, Plug and Play is a global innovation platform that aims to "connect the best technology startups with the world's largest corporations".

Sanofi partnered with Plug and Play on Startup Creasphere, which Plug and Play describes as the “first digital health innovation hub in Europe” (click here to read the News story).

Plug and Play said Sanofi also had projects with it in Singapore, Brazil and the US.

Click tags below for more information on topics:

Galenica COVID-19 Adamed Sanofi Consumer Healthcare

Back to Industry News

Share this page: